LIQUAEMIN SODIUM PRESERVATIVE FREE (heparin sodium) by Aspen Surgical is protein, antithrombin iii, to induce a conformational change, which markedly enhances the serine protease activity of antithrombin ii, thereby inhibiting the activated coagulation factors involved in the closing sequence, particularly xa and iia. First approved in 1939.
Drug data last refreshed 15h ago · AI intelligence enriched 1mo ago
LIQUAEMIN SODIUM PRESERVATIVE FREE is a heparin sodium injection approved in 1939 for anticoagulation therapy. It works by enhancing antithrombin III activity to inhibit activated coagulation factors Xa and IIa, preventing thrombus formation without lysing existing clots. This is a legacy injectable anticoagulant used across acute care and perioperative settings.
As an approaching loss-of-exclusivity product with minimal linked job openings, the brand team is likely contracted or integrated into a broader anticoagulant portfolio rather than standalone.
protein, antithrombin III, to induce a conformational change, which markedly enhances the serine protease activity of Antithrombin II, thereby inhibiting the activated coagulation factors involved in the closing sequence, particularly Xa and IIa. Small amounts of heparin inhibit Factor Xa, and…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Study With Heparin Sodium in Subcutaneous Administration
Study With Heparin Sodium in Intravenous Administration
Full Dose Tenecteplase (TNK-tPA) Together With Heparin Sodium, Full Dose Tenecteplase With Enoxaparin, Half Dose Tenecteplase Together With Abciximab and Heparin Sodium in Patients With Acute Myocardial Infarction (AMI)
Worked on LIQUAEMIN SODIUM PRESERVATIVE FREE at Aspen Surgical? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on LIQUAEMIN SODIUM PRESERVATIVE FREE offers minimal career acceleration; the product is approaching LOE with zero open positions and faces intense generic/therapeutic substitution pressure. Career value lies in hospital dynamics expertise and defensive strategy execution rather than growth trajectory.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo